MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Atractylenolide I

CAS No. : 73069-13-3

MCE 站：Atractylenolide I

产品活性：Atractylenolide I 是从白术根中得到的倍半萜烯，具有神经保护、抗过敏、抗炎和抗癌等多种生物活性。Atractylenolide I 为 TLR4 的拮抗剂，同时在 A375 细胞中，能够降低 JAK2 和 STAT3 的磷酸化水平。

研究领域：Immunology/Inflammation  |  JAK/STAT Signaling  |  Epigenetics  |  Stem Cell/Wnt

作用靶点：Toll-like Receptor (TLR)  |  JAK  |  STAT

In Vitro: Atractylenolide I (40, 60, 80, 100, 120, 150 μM) dose- ａnd time-dependently reduces the cell viability in human A375 melanoma cells after treatment for 24, 48 ａnd 72 hours. Atractylenolide I (50 ａnd 100 μM) induces apoptosis of A375 cells in a dose-dependent manner at 48 h of treatment. Atractylenolide I (100 μM) significantly reduces protein levels of phosphorylated JAK2 ａnd STAT3 in A375 cells, without effect on total JAK2 ａnd STAT3. Furthermore, Atractylenolide I inhibits the mRNA expression of STAT3-targeted genes, including Bcl-xL, MMP-2 ａnd MMP-9. Atractylenolide I (up to 100 μM) shows no toxicity in normal cells. Atractylenolide I (25, 50 μM) decreases the Ox-LDL induced TNF-α, IL-6 ａnd NO production in VSMCs. Atractylenolide I (12.5, 25 or 50 μM) significantly reduces the level of MCP-1 ａnd inhibits Ox-LDL-induced VSMCs proliferation ａnd migration. Atractylenolide I (25, 50 μM) inhibits positive staining of foam cells, ａnd also significantly decreases lipid accumulation. Atractylenolide I (50 μM) suppresses p38MAPK ａnd NF-κB p65 expression in VSMCs stimulated by Ox-LDL. Atractylenolide I (1, 10, 100 μM) downregulates paclitaxel-induced expression of VEGF ａnd survivin via MyD88-dependent TLR4 signaling in EOC cells.

In Vivo: Atractylenolide I (5, 10 or 20 mg/kg, p.o.) restores the decreased body weight in mice subjected to chronic unpredictable mild stress (CUMS). Atractylenolide I alleviates CUMS-induced depressive-like behavior, attenuates CUMS-induced imbalances in hippocampal neurotransmitter levels ａnd reduces CUMS-induced increases in hippocampal pro-inflammatory cytokine levels ａnd in the NLRP3 inflammasome in the hippocampi of mice.

相关产品：Natural Product Library Plus  |  Bioactive Compound Library Plus  |  Epigenetics Compound Library  |  Immunology/Inflammation Compound Library  |  JAK/STAT Compound Library  |  Kinase Inhibitor Library  |  Stem Cell Signaling Compound Library  |  Natural Product Library  |  Anti-Cancer Compound Library  |  Small Molecule Immuno-Oncology Compound Library  |  Anti-Aging Compound Library  |  Antioxidants Compound Library  |  Oxygen Sensing Compound Library  |  Terpenoids Library  |  Pyroptosis Compound Library  |  Traditional Chinese Medicine Monomer Library  |  Neuroprotective Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Transcription Factor Targeted Library  |  Chloroquine  |  Resatorvid  |  Ruxolitinib  |  Resiquimod  |  Stattic  |  Hydroxychloroquine sulfate  |  AG490  |  Tofacitinib  |  Baricitinib  |  Deucravacitinib  |  Imiquimod  |  C29  |  Fludarabine  |  Upadacitinib  |  AS1517499  |  Niclosamide  |  Fedratinib  |  Artesunate  |  Homoharringtonine  |  TPCA-1  |  Colivelin TFA  |  NSC 74859  |  Peficitinib  |  Pacritinib  |  Napabucasin  |  Pimozide  |  Cryptotanshi

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。